Anebulo Pharmaceuticals’ (ANEB) “Speculative Buy” Rating Reiterated at Benchmark

Anebulo Pharmaceuticals (NASDAQ:ANEB)‘s stock had its “speculative buy” rating reissued by analysts at Benchmark in a report issued on Tuesday,Benzinga reports. They currently have a $8.00 price target on the stock. Benchmark’s target price points to a potential upside of 422.88% from the stock’s current price.

Anebulo Pharmaceuticals Stock Performance

Shares of ANEB opened at $1.53 on Tuesday. The stock has a fifty day moving average of $1.90 and a two-hundred day moving average of $2.11. The company has a market capitalization of $39.67 million, a PE ratio of -5.10 and a beta of -1.00. Anebulo Pharmaceuticals has a fifty-two week low of $1.46 and a fifty-two week high of $3.30.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last released its quarterly earnings data on Wednesday, September 25th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08. As a group, equities research analysts forecast that Anebulo Pharmaceuticals will post -0.52 earnings per share for the current fiscal year.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.